Vinita Singh1, Theresa W Gillespie2,3, Olabisi Lane1, Boris Spektor1, Ali John Zarrabi4, Katherine Egan1, Kimberly Curseen4, Maya Tsvetkova5,6, Jan H Beumer5,6,7, Roman Sniecinski1, Jack W Shteamer1, Jeffery Switchenko8, R Donald Harvey2,9. 1. Department of Anesthesiology, Emory University School of Medicine, Atlanta, Georgia, USA. 2. Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA. 3. Department of Surgery, Emory University School of Medicine, Atlanta, Georgia, USA. 4. Department of Family Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. 5. Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA. 6. Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 7. Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. 8. Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA. 9. Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia, USA.
Abstract
STUDY OBJECTIVE: The objective of our study was to determine safety and pharmacology (pharmacokinetics and preliminary efficacy) of intranasal (IN) ketamine for uncontrolled cancer-related pain. DESIGN: Dose escalation clinical trial. SETTING: Outpatient. PATIENTS: Ten adult patients with uncontrolled cancer-related pain. INTERVENTION: Each patient received escalating doses of ketamine over four visits, each 2-5 days apart: 10 mg IN at visit 1, 10 mg intravenous (IV) at visit 2, 30 mg IN at visit 3, and 50 mg IN at visit 4. MEASUREMENTS: Pain was measured before and after drug administration for up to 4 h using the 11 point (0-10) Numerical Pain Rating Scale (NPRS). MAIN RESULTS: All subjects had advanced cancer, with intractable pain, despite being on moderate dosage of opioids. There was a statistically significant reduction in median NPRS by 1.5 (1-4), 3 (2-3), and 4 (3-5) points at 60 min after receiving the medication and remained decreased by 1.5 (1-2), 2 (1-2) and 1 (1-4) points at the end of the study visit (240 min) with the 10 mg, 30 mg and 50 mg IN dosage, respectively. The median percentage of maximal pain relief being 22.5 (16.6-71.5), 65.5 (40-100), and 69.25 (50-100) for 10 mg, 30 mg and 50 mg IN dosage, respectively and 100 (75-100) with 10 mg IV dose. All side effects (nausea and feeling of unreality) resolved by the end of each study visit. No severe adverse events occurred. CONCLUSION: In this single-institution study, all dosages of IN ketamine administered in the study (10, 30, and 50 mg) provided significant pain relief for intractable cancer-related pain and were well tolerated. The 50 mg dose provided maximal pain relief without major side effects. Further study focused on repeated administration efficacy and safety for cancer-related pain is warranted.
STUDY OBJECTIVE: The objective of our study was to determine safety and pharmacology (pharmacokinetics and preliminary efficacy) of intranasal (IN) ketamine for uncontrolled cancer-related pain. DESIGN: Dose escalation clinical trial. SETTING: Outpatient. PATIENTS: Ten adult patients with uncontrolled cancer-related pain. INTERVENTION: Each patient received escalating doses of ketamine over four visits, each 2-5 days apart: 10 mg IN at visit 1, 10 mg intravenous (IV) at visit 2, 30 mg IN at visit 3, and 50 mg IN at visit 4. MEASUREMENTS: Pain was measured before and after drug administration for up to 4 h using the 11 point (0-10) Numerical Pain Rating Scale (NPRS). MAIN RESULTS: All subjects had advanced cancer, with intractable pain, despite being on moderate dosage of opioids. There was a statistically significant reduction in median NPRS by 1.5 (1-4), 3 (2-3), and 4 (3-5) points at 60 min after receiving the medication and remained decreased by 1.5 (1-2), 2 (1-2) and 1 (1-4) points at the end of the study visit (240 min) with the 10 mg, 30 mg and 50 mg IN dosage, respectively. The median percentage of maximal pain relief being 22.5 (16.6-71.5), 65.5 (40-100), and 69.25 (50-100) for 10 mg, 30 mg and 50 mg IN dosage, respectively and 100 (75-100) with 10 mg IV dose. All side effects (nausea and feeling of unreality) resolved by the end of each study visit. No severe adverse events occurred. CONCLUSION: In this single-institution study, all dosages of IN ketamine administered in the study (10, 30, and 50 mg) provided significant pain relief for intractable cancer-related pain and were well tolerated. The 50 mg dose provided maximal pain relief without major side effects. Further study focused on repeated administration efficacy and safety for cancer-related pain is warranted.
Authors: Rachel Quibell; Eric E Prommer; Mary Mihalyo; Robert Twycross; Andrew Wilcock Journal: J Pain Symptom Manage Date: 2011-03 Impact factor: 3.612
Authors: Marianne Jensen Hjermstad; Peter M Fayers; Dagny F Haugen; Augusto Caraceni; Geoffrey W Hanks; Jon H Loge; Robin Fainsinger; Nina Aass; Stein Kaasa Journal: J Pain Symptom Manage Date: 2011-06 Impact factor: 3.612
Authors: David Cella; Susan Yount; Nan Rothrock; Richard Gershon; Karon Cook; Bryce Reeve; Deborah Ader; James F Fries; Bonnie Bruce; Mattias Rose Journal: Med Care Date: 2007-05 Impact factor: 2.983
Authors: Aaron Woo; Breanne Lechner; Terence Fu; C Shun Wong; Nicholas Chiu; Henry Lam; Natalie Pulenzas; Hany Soliman; Carlo DeAngelis; Edward Chow Journal: Ann Palliat Med Date: 2015-10